Tags : IPH5201

Astrazeneca Expands Existing Deal with Innate Pharma to Strengthen its

Vartika Singh October 23, 2018

Shots: AZ gains complete rights to monalizumab (Anti-NKG2A), also gains option rights to IPH5201 as well as 4 preclinical immuno-oncology molecules Innate gains US and EU rights of Lumoxiti approved […]readmore

Tags : IPH5201

Astrazeneca Expands Existing Deal with Innate Pharma to Strengthen its

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : IPH5201

Astrazeneca Expands Existing Deal with Innate Pharma to Strengthen its

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company